Pharma Pricing & Market Access Outlook Europe - list of speakers 

Avxentyeva Maria, Doctor of Medical Sciences, vice-director of the Research Institute of Clinical and Economical Expertise at Russian State Medical University, professor at the Chair of Public Health and Preventive Medicine at Moscow medical academy named after I.M. Sechenov. Prof. Avxentyeva teaches and performs research and consultancy in the...

As the senior civil servant executive of the PMPRB, Michelle is responsible for the corporate leadership of the agency, including its strategic direction, voluntary compliance and pricing guidelines, and the management of human and financial resources. Michelle has extensive experience in the development of government policy. She worked on...

As a desk officer at the Pharmaceuticals Department of the G-BA, Meriem’s field of expertise focuses on the early benefit assessment of pharmaceuticals under AMNOG, the new German Law for Reforming the Market for Pharmaceuticals. Her main tasks include consulting with the pharmaceutical industry, preparation and presentation of technical issues...

Meindert was trained as a pharmacist in the Netherlands and joined NICE in 2004 as a health technology analyst in London. In 2006 he accepted the post of Associate Director with the responsibility of setting up the new Single Technology Appraisals programme for NICE in Manchester. Meindert has previously worked as a hospital pharmacist and in...

Anna Bucsics was born in Budapest, Hungary and lives in Austria. She received her medical degree from the Karl-Franzens-University of Graz, Austria, where she did postgraudate research work in neuro¬pharma¬cology at the Department of Experimental and Clinical Pharmacology. She was also an instructor there until 1991. After completing her training...

Raf De Wilde, PhD, is an expert in global pricing and market access. He recently accepted the role of Associate Vice President for UBC Global Market Access Consulting, after a career of over 30 years in Johnson & Johnson. Dr. De Wilde introduced Health Economics in J&J in 1991 by leading the first J&J HE team within Marketing Services, and has...

Jim Furniss is Director, Market Access Solutions at Bridgehead International. He has a detailed understanding of pharmaceutical policy, pricing and market access issues throughout Europe and North America and extensive practical experience of Company-Government relations in drug pricing and reimbursement. Prior to moving into consultancy Jim was...

Patrick is Director of Market Access and External Affairs at Bristol Myers Squibb UK. In his role Patrick leads the key market access functions including Government affairs, Communications, Pricing, HTA and Field Access. He represents BMS in a number of Industry groups including the ABPI Value Based Pricing/Cancer Drugs Fund working group, the...

Markus had been with Novartis for 10 years in positions in Market Research, Marketing & Sales Analysis and Market Access. He started his career at GfK Healthcare and Siemens Medical in global market research functions. Markus trained as a sociologist at Friedrich-Alexander University, Erlangen and Duke University, Durham

Anne Lee is a pharmacist and spent her early career in hospital pharmacy, specialising in Medicines Information, working in Edinburgh, Newcastle, and Glasgow. In Newcastle Anne developed a keen interest in the safety of medicines and has edited textbooks on adverse drug reactions and safe prescribing in pregnancy. In 1996 she moved to Glasgow...

Donald Macarthur is an independent analyst, consultant and writer on the pharmaceutical business environment across Europe and parts of Asia. He publishes his own reports at justpharmareports.com and trades as DM Pharma Issues Ltd as a consultant. Issues covered through consultancy projects and/or reports include: • pricing and reimbursement...

Sang Moo Lee MD, PhD is Executive director of Center for New Health Technology Assessment in NECA (National Evidence-based healthcare Collaborating Agency). His background is a clinician, and his major is internal medicine, and his sub-specialty is respiratory and critical medicine. His area of recent work is taking concrete shape of evidence...

Neil Palmer is President and Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing and reimbursement consultancy founded as Palmer D’Angelo Consulting Inc (PDCI) in 1996. In addition to PDCI, Neil has worked with RTI Health Solutions, the Patented Medicine Prices Review Board (PMPRB), Statistics Canada and the Kellogg Centre for ...

Steve Phillips is Director, Health Policy and Reimbursement with Johnson & Johnson’ corporate Government Affairs and Policy office. In this role, he provides leadership and guidance in the area of reimbursement to all J&J operating companies. He has also presented to international audiences on the key lessons of the US DRG experience, and...

Ms. Slutsky has directed the Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ) of the U.S. Department of Health and Human Services since June 2003. Prior to Ms. Slutsky’s appointment as director of COE, she served as acting director of the Center for Practice and Technology Assessment at AHRQ. Most...

Ed Schoonveld is a Principal with ZS Associates in Princeton, NJ and Lead for the firm’s Market Access and Pricing Practice. He has extensive experience in pharmaceutical marketing and pricing from both the corporate pharma and consultancy perspective. He has gained extensive experience in the pharmaceutical industry through various...

Chris joined Bridgehead in 2011 bringing with him extensive practical and academic experience within the pharmaceutical industry, across both Marketing and R&D, over a 30 year career. He has held a number of leadership positions at both Global and European level, having previously been Director of Global Pricing and Market Access (Oncology) at...

Dr Graaff spent 4 years in administration form development in Organon, and 7 years in pharmacokinetics and preclinical development at Solvay. He then made the switch from R&D to policy development and moved to Nefarma, the Dutch Association of the Pharmaceutical Industry. He has acted both as a regulatory expert (6 years) and a biotech and...

Stefan Walzer has 8 years experience in payer strategy and its implementation and is currently General Manager of Assessment in Medicine (located in Germany). He has been working as a payer consultant for various global pharmaceutical and medical device companies in order to successfully launch their products across the world. Dr Walzer has also...

Colin Wight, Chief Executive, founded GalbraithWight Ltd 15 years ago in January 1997. Dedicated 100% to healthcare, GalbraithWight specialises in global healthcare Consultancy including market access & commercial excellence, and Learning & Development solutions from the GalbraithWight Business School which delivers training to people from 70...

Dr. Wu obtained her PhD from Institute of Epidemiology, College of Public Health, National Taiwan University: and the subject of her dissertation was the applications of multi-state model to cancer screening using examples from breast cancer screening and colorectal cancer screening. Her research interests majorly focus on the methodological...